| Description | Atacicept (TACI-Ig), a recombinant fusion protein, comprises the extracellular, ligand-binding segment of the TACI receptor fused with the Fc portion of human IgG. It functions by inhibiting B cell activation through binding to both B lymphocyte stimulator and a proliferation-inducing ligand, and is utilized in researching B-cell autoimmune diseases [1] [2]. |
| In vivo | Atacicept（TACI-Ig；100 μg；腹腔注射；每周三次，共14天；BALB/c小鼠）能降低正常小鼠的成熟B细胞数量和血清抗体水平[1]。在胶原诱导型关节炎（CIA）的小鼠模型中，Atacicept（TACI-Ig）抑制了疾病的进展和自身抗体滴度的增加[1]。 |
| Synonyms | TACI-Ig, TACI-Fc 5 |
| molecular weight | N/A |
| CAS | 845264-92-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |